Comparison of Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Solithromycin (CEM-101) in Healthy Adult Subjects
- 1 October 2012
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (10) , 5076-5081
- https://doi.org/10.1128/aac.00766-12
Abstract
The steady-state concentrations of solithromycin in plasma were compared with concomitant concentrations in epithelial lining fluid (ELF) and alveolar macrophages (AM) obtained from intrapulmonary samples during bronchoscopy and bronchoalveolar lavage (BAL) in 30 healthy adult subjects. Subjects received oral solithromycin at 400 mg once daily for five consecutive days. Bronchoscopy and BAL were carried out once in each subject at either 3, 6, 9, 12, or 24 h after the last administered dose of solithromycin. Drug concentrations in plasma, ELF, and AM were assayed by a high-performance liquid chromatography-tandem mass spectrometry method. Solithromycin was concentrated extensively in ELF (range of mean [± standard deviation] concentrations, 1.02 ± 0.83 to 7.58 ± 6.69 mg/liter) and AM (25.9 ± 20.3 to 101.7 ± 52.6 mg/liter) in comparison with simultaneous plasma concentrations (0.086 ± 0.070 to 0.730 ± 0.692 mg/liter). The values for the area under the concentration-time curve from 0 to 24 h (AUC0–24values) based on mean and median ELF concentrations were 80.3 and 63.2 mg · h/liter, respectively. The ratio of ELF to plasma concentrations based on the mean and median AUC0–24values were 10.3 and 10.0, respectively. The AUC0–24values based on mean and median concentrations in AM were 1,498 and 1,282 mg · h/L, respectively. The ratio of AM to plasma concentrations based on the mean and median AUC0–24values were 193 and 202, respectively. Once-daily oral dosing of solithromycin at 400 mg produced steady-state concentrations that were significantly (P< 0.05) higher in ELF (2.4 to 28.6 times) and AM (44 to 515 times) than simultaneous plasma concentrations throughout the 24-h period after 5 days of solithromycin administration.Keywords
This publication has 20 references indexed in Scilit:
- Antibiotics in development targeting protein synthesisAnnals of the New York Academy of Sciences, 2011
- Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining FluidClinical Pharmacokinetics, 2011
- Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophagesBiopharmaceutics & Drug Disposition, 2011
- Pharmacokinetics of Solithromycin (CEM-101) after Single or Multiple Oral Doses and Effects of Food on Single-Dose Bioavailability in Healthy Adult SubjectsAntimicrobial Agents and Chemotherapy, 2011
- CEM-101 Activity against Gram-Positive OrganismsAntimicrobial Agents and Chemotherapy, 2010
- MIC Quality Control Guidelines and Disk Diffusion Test Optimization for CEM-101, a Novel FluoroketolideJournal of Clinical Microbiology, 2010
- In Vitro Activity of CEM-101, a New Fluoroketolide Antibiotic, against Chlamydia trachomatis and Chlamydia ( Chlamydophila ) pneumoniaeAntimicrobial Agents and Chemotherapy, 2010
- In Vitro Activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with Defined Macrolide Resistance MechanismsAntimicrobial Agents and Chemotherapy, 2010
- Cellular Accumulation and Pharmacodynamic Evaluation of the Intracellular Activity of CEM-101, a Novel Fluoroketolide, againstStaphylococcus aureus,Listeria monocytogenes, andLegionella pneumophilain Human THP-1 MacrophagesAntimicrobial Agents and Chemotherapy, 2009
- Comparative In Vitro Susceptibilities of Human Mycoplasmas and Ureaplasmas to a New Investigational Ketolide, CEM-101Antimicrobial Agents and Chemotherapy, 2009